SANUWAVE Health (OTCMKTS:SNWV) and Stryker (NYSE:SYK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Insider & Institutional Ownership
0.4% of SANUWAVE Health shares are owned by institutional investors. Comparatively, 74.6% of Stryker shares are owned by institutional investors. 23.4% of SANUWAVE Health shares are owned by insiders. Comparatively, 7.2% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares SANUWAVE Health and Stryker’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
SANUWAVE Health has a beta of -1.67, meaning that its share price is 267% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Stryker pays an annual dividend of $2.08 per share and has a dividend yield of 1.2%. SANUWAVE Health does not pay a dividend. Stryker pays out 28.5% of its earnings in the form of a dividend. Stryker has raised its dividend for 8 consecutive years.
Valuation and Earnings
This table compares SANUWAVE Health and Stryker’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SANUWAVE Health||$1.85 million||15.48||-$11.63 million||($0.08)||-2.23|
|Stryker||$13.60 billion||4.94||$3.55 billion||$7.31||24.66|
Stryker has higher revenue and earnings than SANUWAVE Health. SANUWAVE Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for SANUWAVE Health and Stryker, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Stryker has a consensus price target of $191.80, indicating a potential upside of 6.40%. Given Stryker’s higher probable upside, analysts clearly believe Stryker is more favorable than SANUWAVE Health.
Stryker beats SANUWAVE Health on 13 of the 16 factors compared between the two stocks.
SANUWAVE Health Company Profile
SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications worldwide. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead product candidate is the dermaPACE device, which has completed its initial Phase III, IDE clinical trial for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 80 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Receive News & Ratings for SANUWAVE Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SANUWAVE Health and related companies with MarketBeat.com's FREE daily email newsletter.